Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW(R) Digital Cytology Microscope - Transforming Veterinary Imaging

Audio By Carbonatix

Cutting-Edge Digital Microscopy System Featured in Monthly Series Showcasing Innovation in Veterinary Care

ANN ARBOR, MI / ACCESS Newswire / September 12, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, is pleased to announce the next installment of its Fourth Friday at Four webinar series, scheduled for Friday, September 26 at 4:00 PM ET, featuring the TRUVIEW digital cytology microscope.

This month's feature will highlight how the TRUVIEW microscope is redefining digital cytology and hematology in veterinary practice by providing rapid, high-quality image capture and interpretation. For the first time in the industry, veterinarians now have the ability to create an automated laboratory-quality blood film on fresh blood-prior to the natural cell bloat caused by EDTA preservatives.

It is well known that best practices require blood films on all blood drawn from a patient. Historically, many clinics have moved away from this standard, not because the practice was incorrect, but due to the lack of technical skill or resources to reliably prepare high-quality slides at the point of care. With the TRUVIEW microscope, those barriers are eliminated, empowering clinicians to return to gold-standard protocols with speed, consistency, and confidence.

What to Expect:

• Demonstration of the TRUVIEW microscope's digital imaging and blood film preparation capabilities

• Insights into how rapid cytology is enhancing diagnostic confidence in clinics

• Discussion of best practices for blood films and how the TRUVIEW microscope enables their adoption at the point of care

• Case studies showcasing real-world improvements in patient outcomes

• Interactive Q&A with Zomedica's leadership and imaging experts

"Zomedica's TRUVIEW microscope brings speed and precision to cytology, which is one of the most critical diagnostic tools veterinarians rely upon," said Bill Campbell, VP of Imaging at Zomedica. "The ability to prepare and analyze a true laboratory-quality blood film on fresh blood, right in the clinic, marks a fundamental shift in veterinary diagnostics."

"Our Fourth Friday series is all about shining a light on innovations that elevate the standard of care in veterinary medicine," said Larry Heaton, CEO of Zomedica. "The TRUVIEW microscope is a perfect example of how our diagnostics portfolio is designed to help veterinarians deliver better outcomes, improve efficiency, and enhance the overall practice experience."

Register for the Webinar

Don't miss your chance to connect with industry experts, get a firsthand look at groundbreaking veterinary technologies, and explore what's next in animal healthcare. Whether you're a veterinary professional, industry partner, investor, or simply passionate about helping our pets live healthier lives, this series is for you.

https://sholink.to/FourthFridayinSeptember

About Zomedica

Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $59 million in liquidity as of June 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com

• LinkedIn: https://www.linkedin.com/company/zomedica

• Facebook: https://m.facebook.com/zomedica

• X (formerly Twitter): https://twitter.com/zomedica

• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations

[email protected]

1-734-369-2555

SOURCE: Zomedica Corp.